ADHD Medication Laws in India: A Plain Language Look at the NDPS Act and Schedule X

Anyone who has spent time on r/ADHDIndia, or in the parents’ WhatsApp groups that orbit Mumbai’s child psychiatry clinics, has heard some version of the same story. The doctor writes a prescription. The pharmacy at the corner says they don’t keep it. The chain pharmacy two metros away does, but only on certain days. The supply went missing for a fortnight in March. The strip you bought last month came in a different box.

It would be easy to read all of this as ordinary Indian-pharmacy chaos. Some of it is. But a meaningful share of it is the predictable consequence of how the law is written. ADHD medication in India sits at the intersection of three regulatory regimes that were not designed with chronic outpatient care in mind, and the friction patients experience is, to a lawyer’s eye, not a bug. It is the law working exactly as drafted.

This piece is a plain language explainer of that legal landscape. It is not advice for any individual case. It is the kind of orientation a curious reader might want before a conversation with a doctor or a lawyer about their own situation.

Two medicines, two regulatory worlds

The two ADHD medications most commonly prescribed in India are methylphenidate and atomoxetine. They sit in completely different parts of the regulatory map.

Methylphenidate is a stimulant. Atomoxetine is a selective noradrenaline reuptake inhibitor, pharmacologically nothing like a stimulant. From a clinical perspective they are alternatives that doctors think about together. From a legal perspective they are barely on the same continent.

Methylphenidate is listed as a psychotropic substance under the schedules of the Narcotic Drugs and Psychotropic Substances Act, 1985 (the NDPS Act, as it is usually shortened). It is also notified under Schedule X of the Drugs and Cosmetics Rules, 1945. Atomoxetine sits under Schedule H, the regular prescription-medicine schedule that covers most of the contents of any Indian pharmacy.

That difference in classification is the entire reason a ground-floor pharmacy in Pune is happy to stock atomoxetine and reluctant to stock methylphenidate. The legal obligations attached to dispensing the two are not in the same league.

What the NDPS Act is actually for

The NDPS Act was enacted in the mid-1980s as the consolidating statute for India’s obligations under the United Nations conventions on narcotic drugs and psychotropic substances. Its drafting context matters: it was a law written about trafficking, abuse, illicit cultivation, and international diversion of controlled substances. Therapeutic outpatient care for chronic conditions was not a central concern of the legislators in 1985.

Therapeutic use is permitted under the Act. Section 8 prohibits production, manufacture, possession, sale, purchase, transport, and use of narcotic drugs and psychotropic substances “except for medical or scientific purposes” and in the manner provided. The whole architecture of authorised manufacturers, licensed pharmacies, prescriptions, registers, and reporting is what makes “medical use” possible at all.

But the regulatory weight is real. Substances scheduled under the NDPS Act are subject to record-keeping, prescription-format, and storage rules that ordinary medicines are not. Penalties under the Act for non-compliant possession or sale are substantial. The economically rational response from a small retail pharmacy is often to simply not stock these substances, because the compliance cost per unit sold is high and the volume is low.

Schedule X and what it requires of pharmacies

Schedule X under the Drugs and Cosmetics Rules, 1945 is the second layer. The Rules require that prescriptions for Schedule X drugs be in duplicate, with one copy retained by the dispensing pharmacy for a period of two years. The pharmacist must record specific particulars of the patient, the prescriber, and the dispensing event. Storage requirements are stricter than for ordinary medicines. The pharmacy must hold the relevant licence categories.

For a small chemist serving a residential neighbourhood, the practical effect is straightforward. Stocking a Schedule X medicine adds bookkeeping, regulatory inspection risk, and audit liability for a class of products that may have one or two regular buyers in the entire catchment. It is easier to tell the customer that the medicine is out of stock and refer them to a larger pharmacy several kilometres away.

This is not a moral failing of pharmacies. It is the predictable outcome of asymmetric compliance costs. Patients experience it as supply unreliability. Lawyers and policy researchers see it as a regulatory design choice that prioritises diversion risk over chronic-care continuity.

Schedule H and Schedule H1, the contrast

Most prescription medicines in India are sold under Schedule H, which requires a prescription but does not impose duplicate-prescription rules or two-year retention. Schedule H1 is a more restrictive subset, created in 2013 to address antibiotic resistance and certain other concerns, that imposes additional record-keeping for specific listed antibiotics, anti-tuberculosis medicines, and a small number of psychotropics. Atomoxetine, in current Indian practice, is dispensed under Schedule H. The compliance burden on the pharmacy is substantially lighter.

This is part of why families navigating ADHD care in India often end up on atomoxetine even where international clinical guidelines might place a stimulant first-line. The choice is partly clinical and partly a function of which medicine the local healthcare system can deliver consistently.

The Mental Healthcare Act, 2017, a different lens

A separate statute, the Mental Healthcare Act, 2017, sits over all of this. It does not specifically address ADHD medication, but it does set out a rights-based framework for persons with mental illness in India.

Section 21(4) of the Act is the headline provision for many readers. It requires insurers to make provision for medical insurance for the treatment of mental illness on the same basis as physical illness. The Insurance Regulatory and Development Authority of India has subsequently issued circulars directing insurers to implement that parity requirement, and the practical landscape of mental-health insurance coverage in India has been slowly shifting since.

Whether ADHD specifically is covered, in what form, and with what limits varies between insurers and policies. The general direction of travel is toward inclusion; the specifics still need to be checked policy by policy.

Telemedicine, the 2020 Guidelines and the unsettled corner

The Telemedicine Practice Guidelines, 2020 were issued under the Indian Medical Council Act framework and were notified during the early phase of the COVID-19 pandemic. They allow registered medical practitioners to consult patients remotely under defined conditions and categorise medicines by what may be prescribed in tele-consultation versus in-person consultation.

The Guidelines distinguish between List O (over-the-counter and similar), List A (medicines that can be prescribed at first remote consultation), List B (medicines that may be prescribed at follow-up tele-consultation if the patient was previously seen in person for the same condition), and a prohibited list that includes substances scheduled under the NDPS Act. The interaction between this prohibited-list framing and chronic ADHD care that involves NDPS-scheduled medication is the unsettled corner of the law. Practising psychiatrists in India have generally been cautious. Many will diagnose remotely and start non-stimulant treatment but require in-person review for stimulant prescription or refill.

This is not a settled legal position. It is a cautious clinical interpretation of a guideline that itself has not been comprehensively updated for chronic outpatient care in psychiatric conditions.

The Rights of Persons with Disabilities Act, a brief mention

The Rights of Persons with Disabilities Act, 2016 lists “specific learning disabilities” among the disabilities recognised under Indian law. ADHD is not separately enumerated in the Act’s schedule, and there is ongoing interpretive evolution about how attention-deficit / hyperactivity disorder is treated for purposes of educational accommodations and other rights under the Act. Central authorities have issued guidelines from time to time. Case law continues to develop. This is an area where the law on the page is one thing and the implementation experience in CBSE / ICSE / state-board schools and in workplaces with twenty or more employees is often another.

What this regulatory shape produces

Pulling these threads together, the legal landscape produces a few practical patterns that any educated Indian patient eventually notices:

• Atomoxetine is more available than methylphenidate, even though some clinical guidelines elsewhere place stimulants first-line. This is partly a regulatory artefact, not a purely clinical preference.
• Methylphenidate availability fluctuates because retail pharmacies face asymmetric compliance costs that make stocking marginal.
• Tele-consult continuity for chronic ADHD care that includes a stimulant is constrained by the cautious interpretation of the 2020 Guidelines.
• Insurance coverage has improved on paper since the Mental Healthcare Act, 2017, but the specifics still vary across policies.
• Educational and workplace accommodations depend on the interaction between the Rights of Persons with Disabilities Act, central guidelines, school or employer practice, and judicial interpretation.

None of this is unique to ADHD. India regulates other chronic-care medications with similar tensions between diversion-risk control and continuity of care. ADHD is just where, for many readers, the friction first becomes personally visible.

A note on what is changing

Statutes and rules in this area are not frozen. The schedules under the Drugs and Cosmetics Rules are amended from time to time. The interaction between the Telemedicine Practice Guidelines and chronic psychiatric care is the subject of continuing professional and academic discussion. The Digital Personal Data Protection Act, 2023, as it is operationalised, will bring new layers around health-data processing. The Rights of Persons with Disabilities framework continues to be interpreted by tribunals and courts.

A summary written today is a snapshot. The direction of travel, toward parity, toward rights-based framing, toward more sensible chronic-care practice, is broadly visible. The pace is slow.

Frequently asked questions

Is methylphenidate banned in India?

No. It is a regulated prescription medicine, scheduled under the NDPS Act and Schedule X of the Drugs and Cosmetics Rules. It can be dispensed lawfully on a valid prescription by a pharmacy holding the relevant licences. Availability is uneven for the regulatory reasons described above.

Is atomoxetine easier to access than methylphenidate?

In the experience of most Indian patients, yes, because atomoxetine is dispensed under the regular Schedule H regime while methylphenidate is under Schedule X and the NDPS Act framework.

Do Indian insurers cover ADHD treatment?

The Mental Healthcare Act, 2017 establishes a parity principle, and IRDAI circulars have directed insurers to implement it. Whether ADHD specifically is covered in a given policy depends on the policy. Readers with specific questions should look at their actual policy document or consult their insurer.

Can ADHD be diagnosed by tele-consultation?

The Telemedicine Practice Guidelines, 2020 permit remote consultation by registered medical practitioners. Whether a particular psychiatrist conducts a complete ADHD assessment remotely is a clinical decision that varies by practitioner and patient situation.

Does the law treat ADHD as a disability?

The Rights of Persons with Disabilities Act, 2016 lists specific learning disabilities among the recognised disabilities. The treatment of ADHD specifically is an area of ongoing interpretation. Readers in education or employment situations who are evaluating whether to seek formal accommodations should consult a lawyer about their specific facts.

Sources

• The Narcotic Drugs and Psychotropic Substances Act, 1985 (full text on indiacode.nic.in).
• The Drugs and Cosmetics Rules, 1945, including Schedules H, H1, and X.
• The Mental Healthcare Act, 2017, particularly Section 21(4).
• The Telemedicine Practice Guidelines, 2020 (issued under the Indian Medical Council Act framework).
• The Rights of Persons with Disabilities Act, 2016.
• The Digital Personal Data Protection Act, 2023.